References
- Jung KW, Won YJ, Kong HJ, Lee ES. Prediction of cancer incidence and mortality in Korea, 2018. Cancer Res Treat 2018;50:317-323. https://doi.org/10.4143/crt.2018.142
- National Cancer Screening Business Information System [Internet]. Goyang: National Cancer Center, 2017 Nov 20 [cited 2018 Mar 12]. Available from: http://www.index.go.kr/potal/main/EachDtl-PageDetail.do?idx_cd=1440
- Jain S, Pincus MR, Bluth MH, McPherson RA, Bowne WB, Lee P. Diagnosis and management of cancer using serologic and other body fluid markers. In: Richard A. McPherson, ed. Henry's clinical diagnosis and management by laboratory methods. St. Louis: Elsevier, 2017:1145-1449.
- Liandou E, Hoon D. Circulating tumor cells and circulating tumor DNA. In: Rifai N, Horvath AR, Wittwer CT, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 6th ed. St. Louis: Elsevier, 2018: 1111-1158.
- Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999;18:65-73. https://doi.org/10.1023/A:1006260319913
- Alix-Panabieres C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 2016;6:479-491. https://doi.org/10.1158/2159-8290.CD-15-1483
- Garcia-Olmo DC, Garcia-Olmo D. Biological role of cell-free nucleic acids in cancer: the theory of genometastasis. Crit Rev Oncog 2013;18:153-161. https://doi.org/10.1615/CritRevOncog.v18.i1-2.90
- Shaw JA, Page K, Blighe K, et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res 2012;22:220-231. https://doi.org/10.1101/gr.123497.111
- Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24. https://doi.org/10.1126/scitranslmed.3007094
- El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 2013;424:222-230. https://doi.org/10.1016/j.cca.2013.05.022
- Yu J, Gu G, Ju S. Recent advances in clinical applications of circulating cell-free DNA integrity. Lab Med 2014;45:6-11. https://doi.org/10.1309/LMKKOX6UJZQGW0EA
- Devonshire AS, Whale AS, Gutteridge A, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 2014;406:6499-6512. https://doi.org/10.1007/s00216-014-7835-3
- Bardelli A, Pantel K. Liquid biopsies, what we do not know (yet). Cancer Cell 2017;31:172-179. https://doi.org/10.1016/j.ccell.2017.01.002
- Chaudhuri AA, Binkley MS, Osmundson EC, Alizadeh AA, Diehn M. Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA. Semin Radiat Oncol 2015;25:305-312. https://doi.org/10.1016/j.semradonc.2015.05.001
- Han X, Wang J, Sun Y. Circulating tumor DNA as biomarkers for cancer detection. Genomics Proteomics Bioinformatics 2017;15:59-72. https://doi.org/10.1016/j.gpb.2016.12.004
- Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27:1386-1422. https://doi.org/10.1093/annonc/mdw235
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297. https://doi.org/10.1016/S0092-8674(04)00045-5
- Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014;42:D68-D73. https://doi.org/10.1093/nar/gkt1181
- miRBase: the microRNA database. Release 22 [Internet]. Manchester: Griffiths-Jones lab, 2018 Mar 12 [Cited 2018 Mar 12]. Available from: http://www.mirbase.org/
- Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
- Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20. https://doi.org/10.1016/j.cell.2004.12.035
- Singh R, Ramasubramanian B, Kanji S, Chakraborty AR, Haque SJ, Chakravarti A. Circulating microRNAs in cancer: hope or hype? Cancer Lett 2016;381:113-121. https://doi.org/10.1016/j.canlet.2016.07.002
- Gabali A, Bluth MH. Molecular diagnosis of hematopoietic neoplasms. In: Richard A. McPherson, ed. Henry's clinical diagnosis and management by laboratory methods. St. Louis: Elsevier, 2016:1465-1491.
- Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 1994;86:774-779. https://doi.org/10.1111/j.1365-2141.1994.tb04828.x
- Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-650.
- Park KU, Lee HE, Park DJ, et al. MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis. Clin Chem Lab Med 2009;47:530-536.
- Kolesnikova EV, Tamkovich SN, Bryzgunova OE, et al. Circulating DNA in the blood of gastric cancer patients. Ann N Y Acad Sci 2008;1137:226-231. https://doi.org/10.1196/annals.1448.009
- Hamakawa T, Kukita Y, Kurokawa Y, et al. Monitoring gastric cancer progression with circulating tumour DNA. Br J Cancer 2015;112:352-356. https://doi.org/10.1038/bjc.2014.609
- Fang WL, Lan YT, Huang KH, et al. Clinical significance of circulating plasma DNA in gastric cancer. Int J Cancer 2016;138:2974-2983. https://doi.org/10.1002/ijc.30018
- Park KU, Lee HE, Nam SK, et al. The quantification of HER2 and MYC gene fragments in cell-free plasma as putative biomarkers for gastric cancer diagnosis. Clin Chem Lab Med 2014;52:1033-1040.
- Shoda K, Ichikawa D, Fujita Y, et al. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. Gastric Cancer 2017;20:126-135. https://doi.org/10.1007/s10120-016-0599-z
- Gao Y, Zhang K, Xi H, et al. Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis. Oncotarget 2017;8:6330-6340.
- Rostami A, Bratman SV. Utilizing circulating tumour DNA in radiation oncology. Radiother Oncol 2017;124:357-364. https://doi.org/10.1016/j.radonc.2017.07.004
- Kim K, Shin DG, Park MK, et al. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res 2014;86:136-142. https://doi.org/10.4174/astr.2014.86.3.136
- Huang Z, Zhu D, Wu L, et al. Six serum-based miRNAs as potential diagnostic biomarkers for gastric cancer. Cancer Epidemiol Biomarkers Prev 2017;26:188-196. https://doi.org/10.1158/1055-9965.EPI-16-0607
- Zhang C, Zhang CD, Ma MH, Dai DQ. Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients. World J Gastroenterol 2018;24:1206-1215. https://doi.org/10.3748/wjg.v24.i11.1206
-
Song B, Lin HX, Dong LL, Ma JJ, Jiang ZG. MicroRNA-338 inhibits proliferation, migration, and invasion of gastric cancer cells by the
$Wnt/{\beta}-catenin$ signaling pathway. Eur Rev Med Pharmacol Sci 2018;22:1290-1296. - Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010;11:136-146. https://doi.org/10.1016/S1470-2045(09)70343-2
- Javanmardi S, Aghamaali MR, Abolmaali SS, Mohammadi S, Tamaddon AM. miR-, an oncogenic target miRNA for cancer therapy: molecular mechanisms and recent advancements in chemo and radio-resistance. Curr Gene Ther 2017;16:375-389. https://doi.org/10.2174/1566523217666170102105119
- Sekar D, Krishnan R, Thirugnanasambantham K, Rajasekaran B, Islam VI, Sekar P. Significance of microRNA 21 in gastric cancer. Clin Res Hepatol Gastroenterol 2016;40:538-545. https://doi.org/10.1016/j.clinre.2016.02.010
- Wang Y, Zhou LB, Li XH. S100A4 expression and prognosis of gastric cancer: a meta-analysis. Genet Mol Res 2014;13:10398-10403. https://doi.org/10.4238/2014.December.12.1
- Ling Z, Li R. Clinicopathological and prognostic value of S100A4 expression in gastric cancer: a meta-analysis. Int J Biol Markers 2014;29:e99-e111. https://doi.org/10.5301/jbm.5000054
- Arita T, Ichikawa D, Konishi H, et al. Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res 2013;33:3185-3193.
- Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-554. https://doi.org/10.1038/nm.3519
- Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-714. https://doi.org/10.1038/nrg2634
- Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005;6:109-118. https://doi.org/10.1038/nrg1522
- Umetani N, Hiramatsu S, Hoon DS. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann N Y Acad Sci 2006;1075:299-307. https://doi.org/10.1196/annals.1368.040
- Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018;359:926-930. https://doi.org/10.1126/science.aar3247
- Creemers A, Krausz S, Strijker M, et al. Clinical value of ctDNA in upper-GI cancers: a systematic review and meta-analysis. Biochim Biophys Acta 2017;1868:394-403.
- Lowes LE, Bratman SV, Dittamore R, et al. Circulating tumor cells (CTC) and cell-free DNA (cfDNA) workshop 2016: scientific opportunities and logistics for cancer clinical trial incorporation. Int J Mol Sci 2016;17:E1505. https://doi.org/10.3390/ijms17091505